Diagnostic Workup for Diffuse Large B-Cell Lymphoma

Introduction to Diagnostic Approach

• The European Society for Medical Oncology recommends a workup for diffuse large B-cell lymphoma that includes tissue diagnosis with immunohistochemistry, comprehensive staging with CT imaging and bone marrow biopsy, PET/CT scanning, laboratory assessment including LDH and viral screening, and risk stratification using the International Prognostic Index 1

Tissue Diagnosis and Pathology

• The American Society of Clinical Oncology suggests obtaining an excisional lymph node biopsy or adequate tissue specimen to provide sufficient material for comprehensive pathological evaluation, with core needle biopsies acceptable only in emergency situations where surgical biopsy is not feasible 1
• A mandatory immunohistochemistry panel must include CD45, CD20, and CD3 to confirm B-cell lineage and CD20 positivity, essential for rituximab eligibility, according to the National Comprehensive Cancer Network 1

Laboratory Assessment and Baseline Studies

• The European Society for Medical Oncology recommends completing baseline laboratory studies including complete blood count, comprehensive metabolic panel with lactate dehydrogenase (LDH) and uric acid, HIV, hepatitis B, and hepatitis C screening, which are critical for IPI calculation and tumor lysis risk assessment 1, 3

Imaging Studies for Staging

• The American College of Radiology recommends a CT scan of chest, abdomen, and pelvis as the minimum staging imaging, with PET/CT scanning strongly recommended for superior disease delineation and accurate post-treatment response assessment according to revised response criteria 1, 3
• PET/CT provides better extent-of-disease assessment than CT alone and is highly recommended to define complete remission, but routine surveillance PET scans during follow-up are not recommended 1, 4, 5

Bone Marrow Evaluation and Staging

• The American Society of Clinical Oncology suggests performing bone marrow aspirate and biopsy in all patients amenable to curative therapy, required for complete staging according to Ann Arbor classification, with repeat assessment at end of treatment only if initially involved 1, 4, 5

Risk Stratification and Prognostic Index

• The National Comprehensive Cancer Network recommends calculating the International Prognostic Index (IPI) and age-adjusted IPI (aa-IPI) using age, elevated LDH, ECOG performance status, Ann Arbor stage, and extranodal sites, which directly influences treatment strategy selection and intensity 1, 3
• The IPI score is a strong predictor of outcome, with higher scores indicating a need for more aggressive approaches, according to the European Society for Medical Oncology 1

Special Considerations and Pitfalls

• The American Society of Clinical Oncology recommends avoiding dose reductions of chemotherapy due to hematological toxicity and instead maintaining dose intensity and using prophylactic growth factors, and assessing for tumor lysis syndrome risk and planning prophylaxis in cases with high tumor burden 1, 3